| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,730,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Equillium is a clinical-stage biotechnology company to develop therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Co.'s pipeline is focused on developing itolizumab (EQ001), EQ101 and EQ102 as potential disease modifying treatments for multiple severe immuno-inflammatory disorders. Co. has active clinical development programs for itolizumab (EQ001) for the treatment of acute graft-versus-host disease and lupus/lupus nephritis. Co. also has a proprietary product discovery platform that it can utilize to design peptides to target and inhibit multiple cytokines that are involved in validated biological and disease pathways.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
12,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$32,410 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothman Joel |
Chief Development Officer |
• – – |
2021-06-10 |
4 |
A |
$2.35 |
$18,194 |
D/D |
7,742 |
22,991 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2021-06-08 |
4 |
S |
$7.18 |
$75,315 |
D/D |
(10,495) |
993,000 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2021-06-08 |
4 |
OE |
$4.75 |
$49,851 |
D/D |
10,495 |
1,003,495 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2021-06-07 |
4 |
S |
$7.08 |
$159,409 |
D/D |
(22,390) |
993,000 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2021-06-07 |
4 |
OE |
$2.80 |
$89,797 |
D/D |
22,390 |
1,006,900 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2021-06-04 |
4 |
S |
$7.01 |
$94,846 |
D/D |
(13,539) |
993,000 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2021-06-04 |
4 |
OE |
$2.80 |
$51,618 |
D/D |
13,539 |
1,000,030 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2021-05-26 |
4 |
AS |
$6.50 |
$32,484 |
I/I |
(5,000) |
115,720 |
|
- |
|
| Cui Xiangmin |
10% Owner |
– – • |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,285,710 |
|
- |
|
| Rothman Joel |
Chief Development OfficerOffic |
• – – |
2021-01-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,249 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2020-12-28 |
4 |
AS |
$4.52 |
$113,045 |
D/D |
(25,000) |
993,000 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2020-12-23 |
4 |
AS |
$4.74 |
$37,914 |
I/I |
(8,000) |
120,720 |
|
- |
|
| Zedelmayer Christine |
Sr. Vice President and COO |
• – – |
2020-12-10 |
4 |
A |
$2.35 |
$2,578 |
D/D |
1,097 |
81,477 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2020-12-10 |
4 |
A |
$2.35 |
$12,601 |
D/D |
5,362 |
12,176 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2020-09-28 |
4 |
AS |
$5.62 |
$140,395 |
D/D |
(25,000) |
1,018,000 |
|
- |
|
| Connelly Stephen |
Chief Scientific Officer |
• • – |
2020-07-13 |
4 |
AS |
$8.13 |
$2,033,475 |
D/D |
(250,000) |
1,043,000 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2020-06-10 |
4 |
A |
$2.41 |
$12,084 |
D/D |
5,014 |
6,814 |
|
- |
|
| Zedelmayer Christine |
Sr. Vice President and COO |
• – – |
2020-06-10 |
4 |
A |
$2.41 |
$23,064 |
D/D |
9,570 |
80,380 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2020-02-18 |
4 |
AS |
$5.03 |
$25,138 |
I/I |
(5,000) |
130,520 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2020-01-21 |
4 |
AS |
$4.41 |
$22,043 |
I/I |
(5,000) |
135,520 |
|
- |
|
| Zedelmayer Christine |
Sr. Vice President and COOOffi |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
70,810 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2019-09-03 |
4 |
AS |
$3.60 |
$17,981 |
I/I |
(5,000) |
138,720 |
|
- |
|
| Keyes Jason A |
Chief Financial Officer |
• – – |
2019-08-01 |
4 |
AS |
$3.99 |
$19,941 |
I/I |
(5,000) |
143,720 |
|
- |
|
| Biocon Sa |
10% Owner |
– – • |
2018-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
228,060 |
2,316,134 |
|
- |
|
| Bradbury Daniel |
Chief Executive Officer |
• • – |
2018-10-16 |
4 |
A |
$11.20 |
$543,144 |
I/I |
48,495 |
2,969,596 |
|
- |
|
51 Records found
|
|
Page 2 of 3 |
|
|
